Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $1.00 by Analysts at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target lowered by research analysts at Royal Bank Of Canada to $1.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 118.34% from the stock’s previous close.

A number of other research firms have also recently commented on EYPT. Cantor Fitzgerald cut shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Citigroup dropped their price target on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. TD Cowen cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $20.00 to $4.00 in a research note on Wednesday, September 2nd. Finally, Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals presently has an average rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Price Performance

Shares of Eyepoint Pharmaceuticals stock traded up $0.02 during trading hours on Tuesday, reaching $0.46. The company’s stock had a trading volume of 11,173,863 shares, compared to its average volume of 3,069,480. The firm has a 50 day moving average price of $4.77 and a 200-day moving average price of $10.30. Eyepoint Pharmaceuticals has a one year low of $0.40 and a one year high of $19.11. The stock has a market cap of $39.48 million, a P/E ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The business had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts forecast that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in Eyepoint Pharmaceuticals in the 1st quarter valued at about $29,000. Integrated Wealth Concepts LLC purchased a new stake in Eyepoint Pharmaceuticals in the 2nd quarter valued at about $72,000. Pictet Asset Management Holding SA purchased a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter worth approximately $141,000. Engineers Gate Manager LP purchased a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth approximately $161,000. Finally, Janney Montgomery Scott LLC lifted its position in shares of Eyepoint Pharmaceuticals by 14.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock worth $391,000 after purchasing an additional 3,900 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Some analysts see potential recovery value at the current price. Mizuho maintained its neutral rating while assigning a $0.50 price target, and Jefferies moved to hold with a $1.00 target. These targets imply substantial upside from the current $0.44 level, although both firms remain cautious. TickerReport analyst coverage
• Positive Sentiment: Unusual options activity included the purchase of 7,885 call contracts, about 69% above typical daily volume, suggesting some traders are positioning for a potential rebound. However, options activity is not confirmation of a fundamental recovery.
• Neutral Sentiment: HC Wainwright and Mizuho reaffirmed neutral ratings. Their stance indicates limited conviction that the remaining pipeline currently supports a bullish investment case.
• Negative Sentiment: JPMorgan downgraded EyePoint from neutral to underweight, while Guggenheim cut its rating from buy to neutral. The downgrades reflect reduced confidence after the LUCIA setback.
• Negative Sentiment: EyePoint is cutting 53% of its workforce and halting wet AMD clinical trials early after disappointing LUCIA results. The company is redirecting resources toward DURAVYU’s diabetic macular edema program, but the restructuring underscores the loss of a major development catalyst. Benzinga workforce and clinical-trial report
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses after the trial disclosure. The investigation adds legal and reputational risk. Levi and Korsinsky investigation notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.